ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 837

Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network

Brigitte Michelsen1, Lykke Midtbøll Ørnbjerg 2, Anne Gitte Loft 3, Tore Kvien 4, Adrian Ciurea 5, Herman Mann 6, Kari K. Eklund 7, Ayten Yazici 8, Maria José Santos 9, Johan Askling 10, Ziga Rotar 11, Bjorn Gudbjornsson 12, Manuel Pombo-Suarez 13, Catalin Codreanu 14, Irene van der Horst-Bruinsma 15, Eirik Kristianslund 16, Michael J. Nissen 17, Karel Pavelka 6, Nina Trokovic 18, Nevsun Inanc 19, Elsa Vieira-Sousa 20, Daniela DiGuiseppe 21, Matija Tomsic 22, Arni Jon Geirsson 23, Ruxandra IONESCU 24, Marleen van de Sande 25, Florenzo Iannone 26, Carlos Sánchez-Piedra 27, Gareth Jones 28, Lise Hyldstrup 2, Merete Lund Hetland 29 and Mikkel Østergaard 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 3Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 4Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 5University Hospital Zürich, Zürich, Switzerland, 6Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 7ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, 8Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10Karolinska Institutet, Stockholm, Sweden, 11UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 12Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 13Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 14Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 15Amsterdam University Medical Center, Amsterdam, Netherlands, 16Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, 17University Hospital Geneva, Geneva, Switzerland, 18Helsinki University Central Hospital, Helsinki, Finland, 19Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, 20Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, 21Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, 22Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 23Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, 24SPITALUL CLINIC SFANTA MARIA, Bucharest, 25Amsterdam UMC, Amsterdam, Netherlands, 26Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 27Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 28University of Aberdeen, Aberdeen, United Kingdom, 29DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 30Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: , , ,

Session Information

Date: Sunday, November 10, 2019

Title: 3S076: Patient Outcomes, Preferences, & Attitudes I: Patient Reported Outcomes (833–838)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common.1 However, the impact of such discordance on retention and remission rates of TNF inhibitor (TNFi) therapy in axial spondyloarthritis (axSpA) patients remains unexplored. Hence, the aim of this study was to assess the impact of baseline discordance, defined as “patient’s minus evaluator’s global assessment of disease activity” (ΔPEG), on retention and remission rates of a first TNFi in axSpA patients across Europe.

Methods: AxSpA patients from 10 European registries participating in the European Spondyloarthritis Research Collaboration Network (EuroSpA) were included. Retention rates after 6/12/24 months’ treatment with first TNFi were assessed with Kaplan-Meier analyses, with comparison between baseline ΔPEG quartiles with log rank test, stratified by gender. Proportions of patients in BASDAI remission (≤2) and ASDAS inactive disease (< 1.3) after 6/12/24 months for different ΔPEG quartiles were compared with Chi-square test, stratified by gender.

Results: A total of 9013 axSpA patients were included. Mean (SD) age for women (n=3639)/men (n=5374) were 42.7(12.0)/41.7(12.0) years, disease duration 5.1(7.4)/6.9(8.7) years, median (25-75 percentiles) baseline ΔPEG 20(3-42)/15(0-37) mm. TNFi retention rates and proportions of patients achieving BASDAI≤2 and ASDAS< 1.3 after 6/12/24 months were lower for higher quartiles of ΔPEG (table, figure).

Conclusion: In patients receiving their first TNFi, high baseline patient’s compared with evaluator’s global assessment is negatively associated with retention rates as well as proportions of patients achieving BASDAI remission and ASDAS inactive disease after 6, 12 as well as 24 months follow-up, both in female and male axSpA patients. TNFi retention rates were lower for women than for men at all timepoints.

Table. Retention and remission rates of first TNFi in axSpA patients.

Figure. TNFi retention rate across ΔPEG quartiles, censored by 104 weeks.

Disclosure: B. Michelsen, Novartis, 2, 5; L. Midtbøll Ørnbjerg, Novartis, 2; A. Loft, None; T. Kvien, AbbVie, 2, 8, Biogen, 5, 8, Biogen, Egis, Eli Lilly, Hikma, Mylan, Novartis/Sandoz, Oktal, Hospira/Pfizer, Sanofi and UCB, 5, BMS, 8, Celltrion, 8, Egis, 5, 8, Eli Lilly, 5, 8, Hikma, 5, 8, Hospira/Pfizer, 2, 5, 8, MSD, 2, 8, Mylan, 5, 8, Novartis, 8, Novartis/Sandoz, 5, 8, Oktal, 5, 8, Orion Pharma, 8, Roche, 2, 8, Sandoz, 8, Sanofi, 5, 8, UCB, 5, 8; A. Ciurea, AbbVie, 5, Celgene, 5, Eli Lilly, 5, Janssen-Cilag, 5, MSD, 5, Novartis, 5, Pfizer, 5, UCB, 5; H. Mann, None; K. Eklund, None; A. Yazici, None; M. Santos, AbbVie, 8, Biogen, 8, Novartis, 8, Pfizer, 8, Roche, 8; J. Askling, AbbVie, 2, BMS, 2, Lilly, 2, MSD, 2, Pfizer, 2, Roche, 2, Samsung Bioepis, 2, UCB, 2; Z. Rotar, AbbVie, 9, Amgen, 5, 8, Eli-Lilly, 9, MSD, 5, Novartis, 9, Pfizer, 9, Sanofi, 5; B. Gudbjornsson, Actavis, 8, Amgen, 8, Novartis, 8, Pfizer, 8; M. Pombo-Suarez, None; C. Codreanu, AbbVie, 5, 8, Egis, 5, 8, Eli-Lilly, 5, 8, Ewopharma, 5, 8, Mylan, 5, 8, Novartis/Sandoz, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB, 5, 8; I. van der Horst-Bruinsma, AbbVie, 2, 5, 8, Bristol Myers-Squibb, 2, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, UCB Pharma, 2, 5, 8; E. Kristianslund, None; M. Nissen, Abbvie, Celgene, Lilly, MSD, Novartis, Pfizer, 5, 8; K. Pavelka, AbbVie, 8, Abbvie, 5, 8, Amgen, 5, 8, BMS, 8, Egis, 5, 8, Lilly, 5, 8, MSD, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB, 8; N. Trokovic, None; N. Inanc, None; E. Vieira-Sousa, None; D. DiGuiseppe, None; M. Tomsic, None; A. Geirsson, None; R. IONESCU, Abbvie, 5, 8, Amgen, 5, 8, Alpha Sigma, 5, 8, BMS, 5, 8, Ewopharma, 5, 8, Lilly, 5, 8, Mylan, 5, 8, Novartis, 5, 8, MSD, 5, 8, Pfizer, 5, 8, UCB, 5, 8, Roche, 5, 8, Sandoz, 5, 8; M. van de Sande, None; F. Iannone, AbbVie, 5, 8, BMS, 5, 8, Janssen, 5, 8, lilly, 5, 8, Lilly, 5, 8, MSD, 2, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, Sanofi, 5, 8, UCB, 5, 8; C. Sánchez-Piedra, None; G. Jones, Celgene, 2; L. Hyldstrup, Novartis, 2; M. Lund Hetland, Abbvie, 2, AbbVie, 2, Biogen, 2, BMS, 2, CellTrion, 2, 9, MSD, 2, Novartis, 2, Orion, 2, Pfizer, 2, Samsung, 2, UCB, 2; M. Østergaard, AbbVie, 2, 8, 9, Abbvie, 2, 5, 8, Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, UCB, 5, 8, Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB, 5, 8, Abbvie, Celgene, Centocor, Merck, and Novartis, 2, Abbvie, Celgene, Centocor, Merck, Novartis, 2, BMS, 2, 5, 8, 9, Boehringer Ingelheim, 5, 8, Boehringer-Ingelheim, 2, 8, Boehringer-ingelheim, 9, Celgene, 2, 5, 8, Centocor, 2, Eli Lilly, 5, 8, 9, Eli Lilly and Company, 5, 8, Eli-Lilly, 2, 8, Hospira, 2, 5, 8, Janssen, 2, 5, 8, 9, Merck, 2, 5, 8, 9, Novartis, 2, 5, 8, Novo, 2, 5, 8, Novo Nordisk, 5, 8, Orion, 2, 5, 8, Pfizer, 2, 5, 8, 9, Regeneron, 2, 5, 8, Roche, 2, 5, 8, roche, 9, Sandoz, 2, 8, Sanofi, 2, 8, UCB, 2, 5, 8.

To cite this abstract in AMA style:

Michelsen B, Midtbøll Ørnbjerg L, Loft A, Kvien T, Ciurea A, Mann H, Eklund K, Yazici A, Santos M, Askling J, Rotar Z, Gudbjornsson B, Pombo-Suarez M, Codreanu C, van der Horst-Bruinsma I, Kristianslund E, Nissen M, Pavelka K, Trokovic N, Inanc N, Vieira-Sousa E, DiGuiseppe D, Tomsic M, Geirsson A, IONESCU R, van de Sande M, Iannone F, Sánchez-Piedra C, Jones G, Hyldstrup L, Lund Hetland M, Østergaard M. Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/does-discordance-between-baseline-patients-and-evaluators-global-assessment-of-disease-activity-impact-retention-and-remission-rates-of-a-first-tnf-inhibitor-in-patients-with-axial-s/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-discordance-between-baseline-patients-and-evaluators-global-assessment-of-disease-activity-impact-retention-and-remission-rates-of-a-first-tnf-inhibitor-in-patients-with-axial-s/